|
PLEKHA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.44089209850063E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.66373598126302E-15 |
| Normal-vs-Stage2 |
5.32907051820075E-15 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
7.815200E-01 |
| Stage1-vs-Stage3 |
1.134420E-02 |
| Stage1-vs-Stage4 |
1.52745999999482E-05 |
| Stage2-vs-Stage3 |
1.152790E-01 |
| Stage2-vs-Stage4 |
9.750600E-04 |
| Stage3-vs-Stage4 |
4.736500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62492241884138E-12 |
| Normal-vs-AfricanAmerican |
6.96331881044898E-13 |
| Normal-vs-Asian |
1.62470037423645E-12 |
| Caucasian-vs-AfricanAmerican |
9.090000E-01 |
| Caucasian-vs-Asian |
6.087400E-01 |
| AfricanAmerican-vs-Asian |
7.949400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
6.66133814775094E-16 |
| Male-vs-Female |
2.008000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.99200722162641E-16 |
| Normal-vs-Age(41-60Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(61-80Yrs) |
<1E-12 |
| Normal-vs-Age(81-100Yrs) |
7.60730000000098E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.693600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.180800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.991400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.204400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.588200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.695000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.678400E-03 |
| Classical-VS-Follicular |
4.899800E-01 |
| Classical-VS-Other |
8.966400E-01 |
| Classical-VS-Normal |
3.33066907387547E-15 |
| Tall-VS-Follicular |
4.079500E-03 |
| Tall-VS-Other |
5.175200E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
8.020600E-01 |
| Follicular-VS-Normal |
1.92068583260152E-14 |
| Other-VS-Normal |
2.398900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.33226762955019E-15 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
3.99899999999898E-05 |
|
|
